| アブストラクト | Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49-9.13) than AKI (ROR = 3.95, 95% CI 3.81-4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89-39.53) and AKI (ROR = 8.18, 95% CI 7.04-9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed. |
|---|
| 組織名 | Department of Pharmacy, West China Hospital, Sichuan University, 37 Guoxue Alley,;Wuhou, Chengdu, 610041, Sichuan, China.;West China School of Medicine, Sichuan University, Chengdu, 610041, Sichuan,;China.;Wuhou, Chengdu, 610041, Sichuan, China. tingx2009@163.com.;West China School of Pharmacy, Sichuan University, Chengdu, 610041, Sichuan,;China. tingx2009@163.com. |
|---|
